Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
EAL | Sinking ship?? | 21/03/24 | 27 | 24K | |||
|
|||||||
EAL | Ann: Suspension and Removal from Official List | 21/05/21 | 1 | 2.3K | |||
|
|||||||
EAL | Ann: Results of Meeting | 13/04/17 | 0 | 662 | |||
|
|||||||
EAL | Ann: Chairman's Address to Shareholders | 12/04/17 | 0 | 1.1K | |||
|
|||||||
EAL | Ann: Notice of Extraordinary General Meeting/Proxy Form | 10/03/17 | 0 | 811 | |||
|
|||||||
EAL | Ann: EAL Announces Delisting from ASX | 10/03/17 | 0 | 1.6K | |||
|
|||||||
EAL | News: EAL E&A ltd plans to delist from Australian Securities Exchange | 10/03/17 | 0 | 1.1K | |||
|
|||||||
EAL | Ann: HY2017 Presentation | 28/02/17 | 0 | 762 | |||
|
See All Discussions